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Summary
Objectives: To study the prevalence, risk factors, outcome, and molecular epidemiology in
patients with bacteremia caused by extended-spectrum b-lactamase (ESBL)-producing Klebsiella
pneumoniae (Kp) (cases), in comparison with patients with bacteremia caused by a susceptible Kp
(controls).
Methods: This was a retrospective case—control study including all episodes of Kp bacteremia for
the period 1993 to 2002 at a referral hospital for adults in Mexico. ESBL production was tested for
by E-test. All isolates were typed by pulsed field gel electrophoresis (PFGE). A subset of isolates
underwent plasmid analysis, conjugal transfer of cefotaxime resistance to Escherichia coli J53-2,
isoelectric focusing bioassay, colony-blot hybridization, PCR, and sequencing.
Results: Of the 121 patients with bacteremia due to Kp included in the study, 17 (14.0%) had an
ESBL-Kp isolate (cases). Multivariate analysis identified prior use of cephalosporins (OR 7.6, 95% CI
1.1—53.5; p = 0.039) and stay in the intensive care unit (ICU; OR 5.6, 95% CI 1.1—27.9; p = 0.033)§ This study was presented in part at the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, USA, September
2004.
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as significant risk factors. No differences were observed in hospital stay or mortality after the
event. Multi-drug resistance was more frequent in ESBL-Kp. There was no clonal predominance. A
distinct b-lactamase profile was identified, which included a combination of TEM-1 (pI 5.4) and
SHV-5 (pI 8.2) in 13/17 ESBL-Kp isolates. Cefotaxime resistance was transferred by conjugation in
14/17 isolates with a >120-kb plasmid encoding ESBL.
Conclusions: The prevalence of ESBL-Kp was found to be lower than that previously reported in
Latin America. ESBL-Kp bacteremia was not associated with a worse clinical outcome. We were
able to identify a plasmid-mediated horizontal dissemination over the 10-year period.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Extended-spectrum b-lactamases (ESBL) are widely distrib-
uted among the Enterobacteriaceae, predominantly in Kleb-
siella pneumoniae and Escherichia coli. These enzymes are
plasmid-mediated and constitute an increasingly important
mechanism of antimicrobial resistance among nosocomial
Gram-negative pathogens.1,2 The highest prevalence of
ESBL-producing K. pneumoniae (ESBL-Kp) worldwide has
been observed in Latin America.3 In Mexico, ESBL-Kp has
mostly been reported causing outbreaks in neonatal intensive
care units. In a multicenter study of urinary and bloodstream
nosocomial infections, the rate of ESBL-Kp was found to be
65%.4—6 Clonal and polyclonal plasmid-mediated horizontal
dissemination of resistance have also been documented in
the hospital setting.7
Resistance mediated by ESBL is of great concern for many
reasons. First, ESBLs can hydrolyze broad-spectrum cepha-
losporins and monobactams.2 Second, these enzymes are
encoded in plasmids that confer resistance to multiple anti-
biotics.1 Third, this type of resistance is not easily detected
by routine antimicrobial susceptibility testing.8 Fourth,
severe infections caused by ESBL-Kp may be associated with
a poor clinical outcome.9,10 The aim of this study was to
describe the prevalence, risk factors, outcome, and mole-
cular epidemiology of the cases of bloodstream infections
caused by ESBL-Kp in a tertiary-care hospital for adults in
Mexico.
Patients and methods
Setting and patients
This study was conducted at the National Institute of Medical
Sciences and Nutrition, a 250-bed referral hospital for adult
patients in Mexico City. A retrospective case—control study
was conducted to assess risk factors for bloodstream infec-
tions due to ESBL-Kp. All patients with positive blood cultures
for K. pneumoniae during the period January 1993 to Decem-
ber 2002 were included. Cases were patients with bacter-
emia caused by ESBL-Kp and controls were patients with
bacteremia due to susceptible K. pneumoniae. Only one
clinical isolate per patient was included. Patients whose
medical records were unavailable were excluded. The fol-
lowing data were obtained: age, gender, length of hospita-
lization, hospital stay prior to the bacteremia, use of
catheters (central venous, arterial, or urinary), nasogastric
tube, or mechanical ventilation, and co-morbid conditions
(liver cirrhosis, malignancy, diabetes mellitus, renal failure(indicated by a creatinine level of2.0 mg/dl or the need for
dialysis), HIV/AIDS, immunosuppressive therapy, active leu-
kemia or lymphoma, or abdominal sepsis). Antimicrobial
therapy received during hospitalization was also recorded.
Microbiological methods
Isolates were identified using Vitek-1 (bioMerieux Vitek, Saint
Louis, MO, USA). Antimicrobial susceptibility to aztrenonam,
cefepime, ceftazidime, ceftriaxone, imipenem, piperacillin/
tazobactam, and ticarcillin/clavulanate; amikacin and gen-
tamicin; ciprofloxacin, gatifloxacin, and ofloxacin, was
determined by microbroth dilution according to Clinical
and Laboratory Standards Institute (CLSI) recommenda-
tions.11 ESBL production was determined by microbroth dilu-
tion according to new guidelines from the CLSI. Briefly, K.
pneumoniae isolates with a ceftazidime minimum inhibitory
concentration (MIC) >1 mg/ml were suspected of harboring
ESBLs. MICs for these isolates were confirmed with ceftazi-
dime alone and in combination with clavulanic acid by E-test
(AB Biodisk, Solna, Sweden). A decrease of>3-fold in the MIC
value for ceftazidime in combination with clavulanic acid
versus the MIC value for ceftazidime alone was considered as
confirmation of ESBL production. E. coli ATCC 25922 and K.
pneumoniae ATCC 700603 were used as negative and positive
controls for ESBL production, respectively.
Genome macro-restriction analysis by pulsed
field gel electrophoresis
Macro-restriction of bacterial genomic DNA was done with
XbaI (Bio-Rad, Richmond, CA, USA). Pulsed field gel electro-
phoresis (PFGE) separation was performed with CHEF-DR-III
Variable Angle System (Bio-Rad). DNA was run at 6 V/cm for
24 h at 14 8C, and the pulse time was increased from 5 s to
40 s. A lambda ladder (New England BioLabs, Beverly, MA,
USA) was used to determine molecular size. Genetic relat-
edness was estimated with the Dice coefficient of similarity.
Isolates were clustered if the degree of relatedness was
0.70. PFGE patterns were analyzed by GelPrint AQ v. 4.0
(Ann Arbor, MI, USA).12 A dendrogram was constructed by the
unweighted pair group method with arithmetic averages.
Isoelectric focusing and bioassay
b-Lactamases were extracted by ultrasonic treatment. Iso-
electric focusing (IEF) was conducted as previously
described13 using a Phast system minigel with a pH range
of 3 to 10 (Pharmacia, Uppsala, Sweden). Extracts from E.
ESBL-producing K. pneumoniae bacteremia 655coli J53-2 encoding TEM-1 (pBR322), SHV-2 (pMG229), and
SHV-5 (pAFF2) ESBLs were used as standards to determine the
isoelectric points (pI) of 5.4, 7.6, and 8.2, respectively. To
determine the ESBLs encoded in the isolates, a bioassay was
performed using cefotaxime (1 mg/ml) in the gel after a mix
of soft agar and a susceptible E. coli (J53-2) culture.
Plasmid isolation and conjugation experiments
Plasmid-DNAwas extracted from all case isolates (N = 17) and
a group of randomly selected controls (N = 17), using stan-
dard methods.14 Matting was performed in filters placed on
solid LB-Luria medium according to Miller,15 using E. coli J53-
2 (F, pro, met, Rifr) as the receptor strain. In all cases,
transconjugants were selected on Luria agar supplemented
with rifampin (100 mg/ml) in combination with cefotaxime
(1 mg/ml), or ampicillin (50 mg/ml). From each successful
matting experiment, 25 independent transconjugants were
obtained from each selection medium and tested on Luria
plates supplemented with ampicillin (100 mg/ml), cefotax-
ime (1 mg/ml), kanamycin (25 mg/ml), tetracycline (25 mg/
ml), chloramphenicol (10 mg/ml), or gentamicin (1 mg/ml).
Transconjugants were denoted with an X before the donor
strain designation.
Plasmid DNA fingerprinting
Plasmid DNA purification from transconjugants and control
clinical isolates was performed with QIAGEN Plasmid Midi Kit
(QIAGEN, Hilden, Germany) ion exchange columns following
the manufacturer’s procedure. Fingerprinting analysis was
performed with PstI restriction enzyme (Promega, Madison,
WI, USA and Gibco BRL, Gaithersburg, MD, USA). The result-
ing DNA fragments were analyzed in 2% agarose gel.
Colony hybridization with blaTEM and blaSHV
probes
All ESBL-Kp isolates and the transconjugants were tested for
colony hybridization.16 Two PCR products were used as
probes, tem and shv. Amplification of blaTEM-related genes
was obtained with DNA of plasmid pBR322 and primers OT1
and OT2, as previously described.17 Primers used for ampli-
fication of blaSHV-related genes were SE5 and SB3 as pre-
viously described,4 using DNA of plasmid pMG229 coding for
SHV-2. Probes were labeled with [a-32P] dCTP using the
Rediprime II kit (Amersham Biosciences, Vienna, Austria)
following the manufacturer’s recommendations.
DNA sequencing of the extended-spectrum
b-lactamases
To determine the enzyme encoded in clinical isolates, five
isolates were selected representing each b-lactamase profile
(2995, 2985, 2982, 2987, and 2989). PCR amplification was
performed using the same primers used for DNA blaSHV probe
(SE5 and SB3). Amplification products were sequenced with
fluorescent-based Taq FS Dye terminator cycle sequencing kit
using the same primers. Sequence analysis was performed
with Genetics Computer Group software and BLASTx search-
ing (EMBL, SwissProt, and PIR databases).18Statistical analysis
Continuous variables were compared using the t-test or
Mann—Whitney U-test. Qualitative variables were compared
using the Chi-square test or Fisher’s exact test, as appro-
priate. Odds ratios (OR) and 95% confidence intervals (CI)
were calculated. Multivariate logistic regression analysis was
performed to determine variables that were independently
associated with the risk of bacteremia caused by ESBL-Kp.
Data were analyzed using the SPSS software package v. 10.0.
Results
Demographic characteristics and risk factors
During the study period, 130 patients with K. pneumoniae
bacteremia were identified. Of these, 121 patients had their
medical records available for review and were included for
further analysis; the median age was 48.1 years (range 15—85
years) and 64 (52.8%) were women. Of the 121 patients, 17
(14.0%) had bacteremia due to ESBL-Kp and were considered
as cases and the other 104 (86.0%) patients were controls.
Sixty-four (52.9%) bacteremia episodes were acquired within
the hospital; all episodes caused by ESBL-Kp (N = 17) were
hospital-acquired in contrast with 47 out of 104 (45.2%)
episodes of bacteremia caused by non-ESBL-producing Kp
( p < 0.0001).
Cases were significantly younger than controls. Addition-
ally, cases were more likely to have had longer hospitaliza-
tions prior to bacteremia (mean 10.4 vs. 29.0 days, p = 0.01)
and to have been admitted to the intensive care unit (ICU)
than controls (Table 1). When co-morbid conditions of the
two groups were compared, cases were significantly more
likely to have leukemia/lymphoma and abdominal sepsis than
controls. Cases were also more frequently intubated, had a
central venous catheter, an arterial catheter, a nasogastric
tube, or a urinary catheter. Cases had more frequently
received cephalosporins, aminoglycosides, and quinolones
than controls (Table 1). After multivariate analysis, only prior
use of cephalosporins (OR 7.6, 95% CI 1.1—53.5; p = 0.039)
and stay in the ICU (OR 5.6, 95% CI 1.1—27.9; p = 0.033)
remained as independent risk factors for bloodstream infec-
tion with ESBL-Kp. A trend for association between ESBL-Kp
bacteremia and previous use of quinolones (OR 6.8, 95% CI
0.9—50.4; p = 0.058) was observed.
Outcome
There was no significant difference between cases and con-
trols in crude mortality rate (35.0% vs. 26.9%; p = 0.47) or in
the mean length of hospitalization after the episode of
bacteremia (mean 20.9 vs.15.9 days; p = 0.49).
Antimicrobial susceptibility
Resistance rates to aminoglycosides, quinolones, ticarcillin/
clavulanate, and piperacillin/tazobactam were higher in
ESBL-Kp. All the isolates were susceptible to imipenem.
Results of antimicrobial susceptibility testing are shown in
Table 2.
Table 1 Clinical characteristics of cases and controls before the episode of Klebsiella pneumoniae bacteremia
Characteristic Cases (N = 17) Controls (N = 104) p
Age, years  SD 35.29  18.32 50.21  17.41 0.001a
Male, n (%) 7 (41.2) 50 (48.1) 0.597b
Stay in ICU, n (%) 15 (88.2) 17 (16.3) <0.001b
Co-morbid conditions
Leukemia/lymphoma 7 (41.1) 15 (14.4) 0.008b
Immunosuppressive treatment 5 (29.4) 15 (14.4) 0.123b
Abdominal sepsis 4 (23.5) 6 (5.8) 0.014b
Diabetes mellitus 3 (17.6) 0 (0) 0.239b
Pancreatitis 2 (11.8) 6 (5.8) 0.356b
End-stage renal disease 1 (5.9) 12 (11.5) 0.485b
Other malignancies 1 (5.9) 19 (18.3) 0.202b
HIV infection 1 (5.9) 4 (3.8) 0.696b
Liver cirrhosis 0 (0) 12 (11.5) 0.140b
Interventions during hospitalization
Central venous catheter 13 (76.5) 49 (47.1) 0.025b
Endotracheal tube 12 (70.6) 30 (28.8) 0.001b
Urinary catheter 12 (70.6) 21 (20.2) <0.001b
Nasogastric tube 6 (35.3) 8 (7.7) 0.001b
Arterial catheter 5 (29.4) 10 (9.6) 0.022b
Surgery 4 (23.5) 35 (33.7) 0.408b
Antibiotic use
Cephalosporins 14 (82.4) 16 (15.4) <0.001b
Aminoglycosides 12 (70.6) 12 (11.5) <0.001b
Quinolones 5 (29.4) 9 (8.7) 0.013b
Ureidopenicillins 2 (11.8) 9 (8.7) 0.679b
Carbapenems 1 (5.9) 1 (1.0) 0.140b
ICU, intensive care unit. Cases: patients with bacteremia caused by extended-spectrum b-lactamase producing K. pneumoniae; controls:
patients with bacteremia due to susceptible K. pneumoniae.
a Student’s t-test or Mann—Whitney U-test.
b Chi-square or Fisher’s exact test.
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All the 121 isolates were typed by PFGE. Fifty-four different
genotypes were identified; 21 isolates were unique and the
remaining 100 were clustered in 33 different genotypesTable 2 Antimicrobial drug resistance of Klebsiella pneumoniae
Antibiotic Cases (N = 17)
Range mg/ml MIC 50/90 % Resis
Amikacin 1—64 16/64 29
Gentamicin 0.125—16 8/16 70
Ofloxacin 0.031—16 1/8 29
Gatifloxacin 0.031—16 0.062/16 29
Ticarcillin/clavulanate 64—128 128/128 100
Piperacillin/tazobactam 2—128 128/128 94
Imipenem 0.031—1 0.031/0.125 0
MIC, minimum inhibitory concentration. Cases: patients with bac
K. pneumoniae; controls: patients with bacteremia due to susceptiblecontaining two to four isolates found throughout the entire
study period. The 17 ESBL-Kp isolates were clustered in 11
genotypes, three of them with two or three isolates but
without epidemiological relatedness after a critical review
(Table 3).among cases and controls
Controls (N = 104) p
tant Range mg/ml MIC 50/90 % Resistant
0.25—16 0 <0.001
0.062—16 0.25/8 17.3 <0.001
0.062—32 0.062/1 7.6 0.007
0.015—8 0.031/0.5 5.7 0.002
1—128 16/128 44.2 <0.001
0.125—128 4/64 20 <0.001
0.031—0.25 0.031/0.125 0 -
teremia caused by extended-spectrum b-lactamase producing
K. pneumoniae.
Figure 1 Representative gel from Pst1 restriction patterns of
plasmids obtained from transconjugant SHV-derived producing
Klebsiella pneumoniae. Lane M, DNA molecular size marker 1-kb
ladder; lane 1, X2986; lane 2, X2984; lane 3, X2985; lane 4,
X2986; lane 5, X2999A; lane 6, X2999B.
Table 3 Molecular characteristics of the 17 extended-spectrum b-lactamase producing Klebsiella pneumoniae clinical isolates
No. strain Year of
isolation
PFGE pattern Plasmid (kb) b-Lactamase
pattern pIa
Transfer of
CTX by
conjugation
b-Lactamase
produced by
transconjuganta
Plasmid
profile
Type
of ESBL
2984 1993 19 200,170,115 5.4,7.6,(8.2) + 5.4,(8.2) A
2985 1993 15 170,70 5.4,7.6,(8.2) + 5.4,(8.2) A SHV-5
2981 1993 27 120,<40 5.4,(8.2) + 5.4,(8.2) A1
2982 1994 14 120,65 5.4,(8.2) + 5.4,(8.2) A1 SHV-5
2990 1997 14 170,120,86 5.4,(8.2) + 5.4,(8.2) A2
2991 2000 16 170 5.4,(8.2) + 5.4,(8.2) A3
2993 2000 27 170 5.4,(8.2) + 5.4,(8.2) A3
2986 1995 3 170,90 5.4,7.7,(8.2) + 5.4,(8.2) A3
2989 1997 14 170 5.4,7.7,(8.2) + 5.4,(8.2) A3 SHV-5
2995 1993 23 170 7.6 + 7.6 A3 SHV-2
2997 1997 18 170,<40 5.4,(8.2) + 5.4,(8.2) A4
2999B 2002 12 170,<40 5.4,7.8,8.0,(8.2) + 5.4,(8.2) B
2999I 2002 19 170,120,54 7.6, (8.2) + (8.2) C
2987 1997 4 120,70 7.6, (8.2) + 7.6, (8.2) D SHV-5
2992 2000 30 120 5.4,7.6,(8.2)  - Eb
2983 1993 18 120 5.4,(8.2)  - Eb
2994 2000 ?? 200,120,86 7.6  - Fb
PFGE, pulsed field gel electrophoresis; CTX, cefotaxime resistance; ESBL, extended-spectrum b-lactamase.
a () Indicate the enzyme with cefotaximase activity (ESBL).
b The plasmid restriction pattern was obtained from the clinical isolate as these strains were not able to transfer resistance by conjugation.
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Each of the 17 ESBL-Kp contained one to three plasmids with
sizes between 40 and 200 kb. We were able to transfer
resistance to ampicillin and cefotaxime in 14 of the 17
isolates studied. Resistance genes were encoded within
the largest plasmid identified. All transconjugants also
expressed resistance to tetracycline, kanamycin, gentami-
cin, and chloramphenicol. We performed an enzyme restric-
tion analysis to seek relationships between these plasmids. A
major pattern A, with four subtypes, was identified in 11
plasmids of 14 transconjugants. This pattern was related in
10 of 11 plasmids expressing the same b-lactamase profile,
which contained two enzymes with pIs of 5.4 and 8.2, with
the exception of transconjugant 2995, which expressed a b-
lactamase with a pI of 7.6. The other three plasmid profiles (B
to D) obtained from the transconjugants were different.
Restriction analysis of the remaining three plasmids that
did not transfer resistance by conjugation showed the same
pattern in two of them (isolates 2992 and 2983) and a
completely unrelated pattern in the last one (isolate 2994)
(Table 3, Figure 1).
Seventeen isolates randomly obtained from the controls
contained from one to three plasmids with sizes between 40
and 200 kb. We could not obtain transconjugants from these
isolates, therefore we prepared a plasmid from each clinical
isolate that was digested with the same restriction enzyme
(PstI). We did not find a pattern among the 17 plasmids from
controls or to those corresponding to the ESBL-Kp plasmids.
IEF analysis and enzyme inhibition test
Results of the IEF analysis are shown in Table 3. Two isolates
exclusively showed an enzyme with a pI of 7.6; another two
isolates showed a profile with pIs of 7.6 and 8.2. The remain-ing 13 isolates had a predominant profile that contained at
least two enzymes with pIs of 5.4 and 8.2; six of these 13
isolates showed an additional enzyme. In all cases, enzymes
with pIs of 8.2 or 7.6 hydrolyzed cefotaxime in the bioassay.
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enzyme suggestive of ESBL activity; in 11 of them, an addi-
tional enzyme with a PI of 5.4 but without ESBL activity was
also identified. Only one transconjugant showed the 7.6 pI
enzyme with ESBL activity.
Molecular hybridization with blaTEM and blaSHV
genes
After molecular hybridization, 11 ESBL-Kp isolates expressing
enzymes with a pI of 5.4 were identified as TEM b-lactamase
producers. All the ESBL-Kp isolates hybridized with the blaSHV
probe, as expected.
Sequencing of ESBL-encoding genes
To identify the type of ESBL encoded in ESBL-Kp, we selected
five of the isolates according to the b-lactamase pattern
obtained by IEF: 2982, 2985, 2987, 2989, and 2995 (Table 3).
Isolates 2982, 2985, 2987, and 2989 expressed the 8.2 ESBL
and contained the Gly238Ser and Glu240Lys substitutions
that corresponded to the SHV-5 b-lactamase. DNA sequence
of the PCR product of isolate 2995 producing the ESBL with a
pI of 7.6 had the amino acid substitution of Gly238Ser, which
corresponded to an SHV-2 enzyme.
Discussion
In this retrospective case—control study, we found that pre-
vious use of cephalosporins ( p = 0.039) and stay in the ICU
( p = 0.033) were independent risk factors for bloodstream
infection with ESBL-Kp. Also, we observed a greater rate of
crude mortality in those cases with an ESBL-producing organ-
ism (35.0%) compared with controls (26.9%), although this
difference was not statistically significant. These factors
have often been reported in other settings, however, they
have been strongly associated with hospital-acquired infec-
tions within outbreaks and with higher crude mortality
rates.19—21 In our hospital, there does not appear to have
been an outbreak situation, as we have demonstrated with
molecular epidemiological tools, but horizontal dissemina-
tion of plasmids that contain ESBLs.22
The outcome in patients infected with ESBL-Kp was
similar, in general terms, to the outcome of controls. There
are several reasons that may explain this finding: (1) Our
results clearly indicate that these isolates are diverse since
they do not seem to be a part of an outbreak or a specific
clone; (2) usually we initially prescribe at least two anti-
biotics to treat any episode of bacteremia, almost always
including a b-lactam and an aminoglycoside; (3) once the
presence of an ESBL-producing organism is confirmed, the
initial therapy is modified accordingly; (4) the number of
ESBL-Kp bacteremias may not be large enough to ensure
statistical power.
These findings support the idea that bacteremia caused by
ESBL-producing K. pneumoniae is not necessarily associated
with a worse outcome. However, in our study and in other
similar studies, other factors may influence the outcome,
mainly patient characteristics (co-morbidities), the hospital
site where the bacteremia was acquired (ICU vs. medical
ward), length of hospitalization, the use of adequate vs.inadequate initial therapy, and an efficient infection control
program.23,24
In contrast to other reports from Latin America, we
identified the most common risk factors for infections due
to ESBL-producing bacteria, but with a much lower preva-
lence.25 The spread and intensity of cephalosporin resistance
among enteric bacteria depend on several factors, and in our
hospital, the horizontal and prolonged carriage of plasmid-
encoded SHV-2 and -5 type b-lactamases seem to be the
source of cephalosporin and multi-drug resistance.26
In summary, our findings highlight the need for a contin-
uous microbiological and molecular screening in ESBL-produ-
cing organisms. This knowledge contributes to the
understanding of the evolution and dissemination of SHV
genes in the hospital setting.
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